Broken biopharm
The engine of biopharmaceutical innovation is broken, according to Eli Lilly's Chairman and CEO, John C. Lechleiter.
The engine of biopharmaceutical innovation is broken, according to Eli Lilly's Chairman and CEO, John C. Lechleiter. Speaking to the City Club of San Diego (CA, USA), which included many business leaders from San Diego's biotech sector, Lechleiter explained that repowering pharmaceutical innovation is an "urgent" need. "At a time when the world desperately needs more new medicines, we're taking too long, spending too much and producing far too little," he said.
He believes that the biotech industry is wasting its potential. Although he acknowledged that several major challenges are facing the industry, such as a loss of trust in product safety and the pressures of the healthcare system, he added that it was a waste of time to complain about these.
Instead, companies should change the way they develop new medicines. In particular, he suggested that collaboration (i.e., working with large and small enterprises, as well as academic and government researchers worldwide) and competency (i.e., taking advantage of advanced scientific tools) could help to boost medical innovation. He also added that patients and improved outcomes should be placed at the center of research from the start of the drug development process.
According to Lechleiter, reinventing biopharm R&D will help regain the public's trust, address the concerns of regulators and demonstrate to policymakers the value that innovative medicines can play.
Why is the PDA Pharmaceutical Microbiology Conference the Hottest Ticket in the Industry?
October 10th 2024Get a glimpse of the power and popularity behind the PDA Pharmaceutical Microbiology Conference from two planning committee members, Julia Marre, PhD (Associate Director, Scientific and Regulatory Affairs at Pocket Naloxone Corp) and Dawn Watson (Executive Director, Global Micro Quality and Sterility Assurance at Merck). This candid conversation reveals why this industry event is so influential…and always sold out! The speakers discuss what makes the PDA Pharmaceutical Microbiology Conference so vital to industry professionals, as well as how to become a part of this dynamic professional community.
Navigating Annex 1 for Early Phase Sterile Fill Finish in Clinical Supplies
November 21st 2024Stay compliant with Annex 1 for early phase sterile fill finish processes. Discover how to implement robust contamination control strategies, integrate isolator technology, and conduct integrity testing to meet stringent European Union standards. The guide provides a comprehensive look at key elements such as PUPSIT, critical zone controls, and monitoring and training for aseptic processes.
Your Ultimate Guide for CMC Testing Support for Gene and Cell Therapy
November 21st 2024Explore the complexities of gene and cell therapy development with our comprehensive guide to Chemistry, Manufacturing, and Controls (CMC) testing. Learn how our expertise ensures the safety, potency, and quality of advanced therapies, supporting your journey from product development through regulatory approval.
